Ubrogepant
Ubrogepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) that blocks CGRP-mediated vasodilation and neurogenic inflammation implicated in migraine pathophysiology. It is approved for acute treatment of migraine attacks with or without aura in adults. Unlike triptans, it does not cause vasoconstriction, making it potentially safer for patients with cardiovascular risk factors.
Moleküler Ağırlık
549,5000 g/mol
LogP
3,10
TPSA
104,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Yapı
Cite this structure
Embed this structure
SMILES
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
InChI
InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
Molecular Formula
C29H26F3N5O3
HBD / HBA
2 / 8
Döndürülebilir Bağlar
4
Ağır Atomlar
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Ubrogepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) that blocks CGRP-mediated vasodilation and neurogenic inflammation implicated in migraine pathophysiology. It is approved for acute treatment of migraine attacks with or without aura in adults. Unlike triptans, it does not cause vasoconstriction, making it potentially safer for patients with cardiovascular risk factors.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Ubrogepant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364638. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68748835. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ubrogepant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ubrogepant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ubrogepant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ubrogepant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ubrogepant"></drugfyi-drug>